{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:18:13Z","timestamp":1784852293251,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"the Translational Research Grant of NCRCH","award":["2020ZKPB02"],"award-info":[{"award-number":["2020ZKPB02"]}]},{"name":"the Suzhou Health Talents Program","award":["GSWS2020039"],"award-info":[{"award-number":["GSWS2020039"]}]},{"name":"the Suzhou Clinical Trial Institution Capacity Enhancement Program","award":["SLT2021003"],"award-info":[{"award-number":["SLT2021003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s40261-023-01266-7","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T09:57:02Z","timestamp":1683799022000},"page":"315-324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy of Eltrombopag with Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone on Severe Aplastic Anaemia: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"43","author":[{"given":"Senlin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingjie","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3386-6957","authenticated-orcid":false,"given":"Shaoyan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"issue":"5","key":"1266_CR1","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1007\/s12185-013-1331-y","volume":"97","author":"SH Shin","year":"2013","unstructured":"Shin SH, Lee JW. The optimal immunosuppressive therapy for aplastic anemia. Int J Hematol. 2013;97(5):564\u201372.","journal-title":"Int J Hematol"},{"issue":"17","key":"1266_CR2","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1056\/NEJMra1413485","volume":"379","author":"NS Young","year":"2018","unstructured":"Young NS. Aplastic anemia. N Engl J Med. 2018;379(17):1643\u201356.","journal-title":"N Engl J Med"},{"issue":"8","key":"1266_CR3","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1182\/blood-2006-03-010777","volume":"108","author":"NS Young","year":"2006","unstructured":"Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108(8):2509\u201319.","journal-title":"Blood"},{"issue":"20","key":"1266_CR4","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1182\/bloodadvances.2019000722","volume":"3","author":"N Bejanyan","year":"2019","unstructured":"Bejanyan N, Kim S, Hebert KM, Kekre N, Abdel-Azim H, Ahmed I, et al. Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Adv. 2019;3(20):3123\u201331.","journal-title":"Blood Adv"},{"issue":"5","key":"1266_CR5","doi-asserted-by":"publisher","first-page":"696","DOI":"10.3324\/haematol.2014.115345","volume":"100","author":"A Bacigalupo","year":"2015","unstructured":"Bacigalupo A, Soci\u00e9 G, Hamladji RM, Aljurf M, Maschan A, Kyrcz-Krzemien S, et al. Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis. Haematologica. 2015;100(5):696.","journal-title":"Haematologica"},{"issue":"1","key":"1266_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.7326\/0003-4819-92-1-30","volume":"92","author":"R Storb","year":"1980","unstructured":"Storb R, Thomas ED, Buckner CD, Clift RA, Deeg HJ, Fefer A, et al. Marrow transplantation in thirty\" untransfused\" patients with severe aplastic anemia. Ann Inter Med. 1980;92(1):30\u20136.","journal-title":"Ann Inter Med"},{"issue":"6","key":"1266_CR7","first-page":"1185","volume":"120","author":"P Scheinberg","year":"2012","unstructured":"Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood J Am Soc Hematol. 2012;120(6):1185\u201396.","journal-title":"Blood J Am Soc Hematol"},{"issue":"4","key":"1266_CR8","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/bjh.13297","volume":"169","author":"C Dufour","year":"2015","unstructured":"Dufour C, Pillon M, Soci\u00e8 G, Rov\u00f2 A, Carraro E, Bacigalupo A, et al. Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant. Br J Haematol. 2015;169(4):565\u201373.","journal-title":"Br J Haematol"},{"issue":"12","key":"1266_CR9","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.3324\/haematol.2014.109355","volume":"99","author":"N Yoshida","year":"2014","unstructured":"Yoshida N, Kobayashi R, Yabe H, Kosaka Y, Yagasaki H, Watanabe K-I, et al. First-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor versus immunosuppressive therapy. Haematologica. 2014;99(12):1784.","journal-title":"Haematologica"},{"key":"1266_CR10","first-page":"9","volume":"2020","author":"P Scheinberg","year":"2020","unstructured":"Scheinberg P. Novel therapeutic choices in immune aplastic anemia. F1000Research. 2020;2020:9.","journal-title":"F1000Research."},{"issue":"10","key":"1266_CR11","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1080\/17474086.2019.1645003","volume":"12","author":"F Pierri","year":"2019","unstructured":"Pierri F, Dufour C. Management of aplastic anemia after failure of frontline immunosuppression. Expert Rev Hematol. 2019;12(10):809\u201319.","journal-title":"Expert Rev Hematol"},{"issue":"16","key":"1266_CR12","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","volume":"376","author":"DM Townsley","year":"2017","unstructured":"Townsley DM, Scheinberg P, Winkler T, Desmond R, Dumitriu B, Rios O, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376(16):1540\u201350.","journal-title":"N Engl J Med"},{"issue":"24","key":"1266_CR13","first-page":"2575","volume":"133","author":"T Winkler","year":"2019","unstructured":"Winkler T, Fan X, Cooper J, Desmond R, Young DJ, Townsley DM, et al. Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag. Blood J Am Soc Hematol. 2019;133(24):2575\u201385.","journal-title":"Blood J Am Soc Hematol"},{"issue":"3","key":"1266_CR14","first-page":"981","volume":"111","author":"K Kaushansky","year":"2008","unstructured":"Kaushansky K. Historical review: megakaryopoiesis and thrombopoiesis. Blood J Am Soc Hematol. 2008;111(3):981\u20136.","journal-title":"Blood J Am Soc Hematol"},{"key":"1266_CR15","first-page":"671","volume":"1","author":"WS Alexander","year":"1996","unstructured":"Alexander WS, Roberts AW, Nicola NA, Li R, Metcalf D. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Cell Stem Cell. 1996;1:671\u201384.","journal-title":"Cell Stem Cell"},{"issue":"6","key":"1266_CR16","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.stem.2007.10.008","volume":"1","author":"H Qian","year":"2007","unstructured":"Qian H, Buza-Vidas N, Hyland CD, Jensen CT, Antonchuk J, M\u00e5nsson R, et al. Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell. 2007;1(6):671\u201384.","journal-title":"Cell Stem Cell"},{"issue":"5","key":"1266_CR17","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s40265-015-0363-4","volume":"75","author":"PL McCormack","year":"2015","unstructured":"McCormack PL. Eltrombopag: a review of its use in patients with severe aplastic anaemia. Drugs. 2015;75(5):525\u201331.","journal-title":"Drugs"},{"key":"1266_CR18","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1182\/blood-2019-131670","volume":"134","author":"J Jinsong","year":"2019","unstructured":"Jinsong J, Jiang H, Huang XJ. Outcome of standard immunosuppressive therapy with or without eltrombopag for Chinese patients with severe aplastic anemia in the real world. Blood. 2019;134:5019.","journal-title":"Blood"},{"issue":"1","key":"1266_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1200931","volume":"367","author":"MJ Olnes","year":"2012","unstructured":"Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367(1):11\u20139.","journal-title":"N Engl J Med"},{"issue":"12","key":"1266_CR20","first-page":"1818","volume":"123","author":"R Desmond","year":"2014","unstructured":"Desmond R, Townsley DM, Dumitriu B, Olnes MJ, Scheinberg P, Bevans M, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood J Am Soc Hematol. 2014;123(12):1818\u201325.","journal-title":"Blood J Am Soc Hematol"},{"key":"1266_CR21","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1182\/blood-2019-124811","volume":"134","author":"EM Groarke","year":"2019","unstructured":"Groarke EM, Patel BA, Diamond C, Gutierrez-Rodrigues F, Vicente A, Rios O, et al. Outcomes in pediatric patients with severe aplastic anemia treated with standard immunosuppression and eltrombopag. Blood. 2019;134:454.","journal-title":"Blood"},{"issue":"7","key":"1266_CR22","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1080\/08880018.2021.1900475","volume":"38","author":"M Jie","year":"2021","unstructured":"Jie M, Fu L, Li S, He Y, Yao J, Cheng X, et al. Efficacy and safety of eltrombopag in the first-line therapy of severe aplastic anemia in children. Pediatr Hematol Oncol. 2021;38(7):647\u201357.","journal-title":"Pediatr Hematol Oncol"},{"issue":"1","key":"1266_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2109965","volume":"386","author":"R Peffault-de-Latour","year":"2022","unstructured":"Peffault-de-Latour R, Kulasekararaj A, Iacobelli S, Terwel SR, Cook R, Griffin M, et al. Eltrombopag added to immunosuppression in severe aplastic anemia. N Engl J Med. 2022;386(1):11\u201323.","journal-title":"N Engl J Med"},{"key":"1266_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88: 105906.","journal-title":"Int J Surg"},{"issue":"1","key":"1266_CR25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1182\/blood.2021012130","volume":"139","author":"BA Patel","year":"2022","unstructured":"Patel BA, Groarke EM, Lotter J, Shalhoub R, Gutierrez-Rodrigues F, Rios O, et al. Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study. Blood. 2022;139(1):34\u201343.","journal-title":"Blood"},{"issue":"7","key":"1266_CR26","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1080\/08880018.2021.1895924","volume":"38","author":"M Fang","year":"2021","unstructured":"Fang M, Song H, Zhang J, Li S, Shen D, Tang Y. Efficacy and safety of immunosuppressive therapy with or without eltrombopag in pediatric patients with acquired aplastic anemia: a Chinese retrospective study. Pediatr Hematol Oncol. 2021;38(7):633\u201346.","journal-title":"Pediatr Hematol Oncol"},{"issue":"8","key":"1266_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29066","volume":"68","author":"H Lesmana","year":"2021","unstructured":"Lesmana H, Jacobs T, Boals M, Gray N, Lewis S, Ding J, et al. Eltrombopag in children with severe aplastic anemia. Pediatr Blood Cancer. 2021;68(8): e29066.","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"1266_CR28","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1182\/bloodadvances.2021006716","volume":"7","author":"O Goronkova","year":"2023","unstructured":"Goronkova O, Novichkova G, Salimova T, Kalinina I, Baidildina D, Petrova U, et al. Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia. Blood Adv. 2023;7(6):953\u201362.","journal-title":"Blood Adv"},{"issue":"3","key":"1266_CR29","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/bjh.17232","volume":"192","author":"EM Groarke","year":"2021","unstructured":"Groarke EM, Patel BA, Gutierrez-Rodrigues F, Rios O, Lotter J, Baldoni D, et al. Eltrombopag added to immunosuppression for children with treatment-na\u00efve severe aplastic anaemia. Br J Haematol. 2021;192(3):605\u201314.","journal-title":"Br J Haematol"},{"issue":"1","key":"1266_CR30","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3324\/haematol.2021.278413","volume":"107","author":"Y Zaimoku","year":"2022","unstructured":"Zaimoku Y, Patel BA, Shalhoub R, Groarke EM, Feng X, Wu CO, et al. Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag. Haematologica. 2022;107(1):126.","journal-title":"Haematologica"},{"issue":"2","key":"1266_CR31","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40261-018-0725-2","volume":"39","author":"Y Hong","year":"2019","unstructured":"Hong Y, Li X, Wan B, Li N, Chen Y. Efficacy and safety of eltrombopag for aplastic anemia: a systematic review and meta-analysis. Clin Drug Investig. 2019;39(2):141\u201356.","journal-title":"Clin Drug Investig"},{"issue":"24","key":"1266_CR32","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1182\/blood.2019000478","volume":"133","author":"T Winkler","year":"2019","unstructured":"Winkler T, Fan X, Cooper J, Desmond R, Young DJ, Townsley DM, et al. Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag. Blood. 2019;133(24):2575\u201385.","journal-title":"Blood"},{"issue":"9","key":"1266_CR33","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1001\/jama.289.9.1130","volume":"289","author":"S Rosenfeld","year":"2003","unstructured":"Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003;289(9):1130\u20135.","journal-title":"JAMA"},{"issue":"2","key":"1266_CR34","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1365-2141.2008.07450.x","volume":"144","author":"P Scheinberg","year":"2009","unstructured":"Scheinberg P, Wu CO, Nunez O, Young NS. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol. 2009;144(2):206\u201316.","journal-title":"Br J Haematol"},{"issue":"4","key":"1266_CR35","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1182\/blood-2005-06-2485","volume":"107","author":"C Sugimori","year":"2006","unstructured":"Sugimori C, Chuhjo T, Feng X, Yamazaki H, Takami A, Teramura M, et al. Minor population of CD55-CD59-blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood. 2006;107(4):1308\u201314.","journal-title":"Blood"},{"issue":"3","key":"1266_CR36","doi-asserted-by":"publisher","first-page":"193","DOI":"10.7326\/0003-4819-130-3-199902020-00004","volume":"130","author":"A Tichelli","year":"1999","unstructured":"Tichelli A, Soci\u00e9 G, Henry-Amar M, Marsh J, Passweg J, Schrezenmeier H, et al. Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. Ann Intern Med. 1999;130(3):193\u2013201.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1266_CR37","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/bjh.17190","volume":"192","author":"JH Jang","year":"2021","unstructured":"Jang JH, Tomiyama Y, Miyazaki K, Nagafuji K, Usuki K, Uoshima N, et al. Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II\/III, multicentre, open-label study. Br J Haematol. 2021;192(1):190\u20139.","journal-title":"Br J Haematol"},{"issue":"7","key":"1266_CR38","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/s41409-019-0452-1","volume":"54","author":"LP Zhao","year":"2019","unstructured":"Zhao LP, Sicre-De-Fontbrune F, Contejean A, Abraham J, Terriou L, Chabrot C, et al. Nationwide survey in France on the use of romiplostim in patients with refractory severe aplastic anemia. Bone Marrow Transplant. 2019;54(7):1161\u20133.","journal-title":"Bone Marrow Transplant"},{"key":"1266_CR39","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.exphem.2022.11.002","volume":"117","author":"Y Chi","year":"2023","unstructured":"Chi Y, Hu Q, Yang C, Chen M, Han B. Avatrombopag is effective in patients with chemoradiotherapy-induced aplastic anemia: a single-center, retrospective study. Exp Hematol. 2023;117:62\u20138.","journal-title":"Exp Hematol"},{"issue":"1","key":"1266_CR40","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000506387","volume":"144","author":"J Tu","year":"2021","unstructured":"Tu J, Pan H, Li R, Wang Z, Lian Y, Li W, et al. PNH Clones for aplastic anemia with immunosuppressive therapy: A systematic review and meta-analysis. Acta Haematol. 2021;144(1):34\u201343.","journal-title":"Acta Haematol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01266-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-023-01266-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01266-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T09:43:16Z","timestamp":1684489396000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-023-01266-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1266"],"URL":"https:\/\/doi.org\/10.1007\/s40261-023-01266-7","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"2 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by the Translational Research Grant of NCRCH, No. 2020ZKPB02, the Suzhou Health Talents Program, GSWS2020039, and the Suzhou Clinical Trial Institution Capacity Enhancement Program, SLT2021003.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Senlin Zhang, Qingwei Wang, Kai Cui, Bingjie Cheng, Junjie Fan and Shaoyan Hu declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No ethical approval was required because this study synthesised and analysed data from previously published studies and did not involve any participants or patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All data sources are included in this published article and electronic supplementary materials.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Senlin Zhang and Qingwei Wang: literature search, statistical analysis, data extraction, interpretation of the data, and drafting of the manuscript. Kai Cui and Bingjie Cheng: Statistical analyses and data extraction. Shaoyan Hu and Junjie Fan: data interpretation, interim discussion, and manuscript revision.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}